Latest News and Press Releases

ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...

  Dr. Cavey verfügt über langjährige Berufserfahrung in der radiopharmazeutischen Industrie und wird die Weiterentwicklung von ITMs Pipeline und das Unternehmenswachstum maßgeblich unterstützen....

  With a significant track record of success in the radiopharmaceutical industry, Dr. Cavey will help accelerate ITM’s pipeline and business growth  Garching /...

Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...

Leveraging profound knowledge in radiopharmaceutical drug development and commercial planning, Dr. Meyrick will lead the medical team in further developing and delivering on ITM's pipeline...

A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...

License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and...

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...

Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its...

Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP manufacturing capabilities to...